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Summary Epidermal growth factor receptors and insulin like growth factor-I receptors were co-expressed on
two gastric and three colorectal tumour cell lines. Previous studies have shown that gastrin receptors were also
expressed at a low level or two of these cell lines. Both TGFa and IGF-I promoted cell growth in all of the
cell lines tested. The cell doubling time of a colorectal cell line was reduced from 48 to 30-34 h. Furthermore
the effects of the growth factors were additive. Each growth factor also increased the response of the cells to
gastrin, but a combination of both growth factors and gastrin did not further increase growth.
The growth of gastrointestinal mucosa is regulated by
numerous hormones and growth factors. However the factors
controlling growth of tumours arising in these tissues are not
as well understood. Previous studies have shown that the
hormone gastrin plays a central role in the stimulation of gut
tumour proliferation (Townsend et al., 1988; Morris et al.,
1989b; Watson et al., 1988, 1989b,c).
Similarly other groups have shown that the growth factors
EGF/TGFx and IGF-I may be implicated in the autocrine
control of gastric and colorectal tumour cell growth. Tahara
et al. (1986), used immunological techniques to show elevated
expression of EGF in advanced gastric tumours, which was
related to differentiation and to patient prognosis. Using
immunohistology Yasui et al. (1988) detected EGF receptor
in gastric cancer, including 3% of early tumours and 34% of
advanced tumours. They also showed that growth of some of
their gastric cell lines was promoted by the addition of EGF
(Miyamori et al., 1986). However, Coffey et al. (1986) did not
see a similar mitogenic reponse to TGFx in a colorectal cell
line which expressed the EGF receptor.
In a large study with a wide variety of tumours Derynck et
al. (1987) showed that EGF receptor and TGFax mRNAs
were expressed at higher levels in the tumour than the corre-
sponding normal tissue. In a more recent study concurrent
expression of mRNA for TGFa and its receptor was more
frequently found in gastric tumours (38%) than in the adja-
cent normal mucosa (7%). Higher levels of TGFa mRNA
were found in tumour than adjacent normal tissue (Bennett
et al., 1989). These results suggest that TGFa is more
involved with the growth of the tumour than the normal
mucosa.
IGF-I has also been implicated in regulating colorectal
tumour cell growth as Tricoli et al. (1986) demonstrated
elevated expression of IGF-I and -II in human colon carcin-
omas. It has also been shown that the colorectal cell line
HT29 simultaneously produces insulin like growth factor-I
and EGF competing factors (Culouscou et al., 1987).
This study was designed to investigate whether these fac-
tors acted independently or were additive in controlling
tumour cell growth. A series of recently developed gastric
and colonic tumour cell lines and an established gastric
cancer cell line were screened for the presence of receptors
and the mitogenic effects of gastrin, IGF-I and TGFa.
Materials and methods
Cell lines
C146, C168 cell lines were derived by growth in soft agar
from a large adenoma and an advanced colorectal cancer
respectively (Durrant et al., 1986). Cell lines 277, 280 were
derived from primary colorectal tumours and Stl6 from a
gastric tumour by growth on primaria plates (Flow Labs,
Irvine, UK; Durrant et al., 1987). Three new cell lines C523,
C560, both of colonic tumour origin, and St42 derived from
an advanced gastric tumour have recently been established by
growth on normal tissue culture plates. MKN45 is a human
adenocarcinoma cell line originally derived from a metastatic
tumour of the stomach (Hojo, 1977). All the cell lines were
routinely grown in DMEM supplemented with 10% foetal
bovine serum (Gibco, Paisely, Fife). Prior to incubation with
the growth factors they were washed twice in serum free
medium and plated in 1:1 mixture of Hams F12:Eagle's
medium containing 0.1% BSA (Sigma, Poole, Dorset) and
left for 4-18 h.
Receptor measurements
Cells were grown in serum free medium for 48 h prior to
receptor measurements. Cells were harvested by rubber
policemen, counted and incubated with either radiolabelled
IGF-I (10 ng ml-') (Amersham International) or radio-
labelled EGF (1Ong ml-') in the presence or absence of a
1,000 fold excess of unlabelled specific and nonspecific ligand
(Hoosien et al., 1987). The amount of specific binding is the
amount which can be dissociated in the presence of excess
unlabelled ligand. The amount of specific binding always
exceeded the amount of background binding in the presence
of an excess of unlabelled ligand by three standard deviations
of the mean to ensure meaningful results. These experiments
are performed on quadruplicated samples and have been
repeated three times this permits the number of molecules of
ligand binding to each cell to be estimated and allows cal-
culation of the approximate number of receptors per cell.
Assessment ofcell growth
Cells were plated at 2 x 104 cells per well in serum free
growth medium. After resting the cells for 4-18 h at 37°C
the growth factors were added and 48 h later cells were
assessed for growth by 75Se-selenomethionine incorporation
(Watson et al., 1988). To compare selenomethionine incor-
poration with cell proliferation, the cell line C146 which
showed intermediate levels of selenomethionine incorpora-
tion, was also analysed for response to mitogens by direct
counting of cells.
Tumour cell doubling times were calculated by growing
replicate culture of cells at 104 per well in serum free medium
in the presence or absence of growth factors in 24 well tissue
culture plates. Duplicate wells were harvested daily and cells
were counted by haemocytometer. TGFa and IGF-I were
both recombinant growth factors and were obtained from
Bachem Inc., Saffron Walden, UK. The human gastrin (G17)
was obtained from Sigma, Dorset, UK. All growth factors
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were tested from 1 pg ml-' to 1 fig ml-' which covers the
normal physiological dosage. Results are expressed as the
mean ± s.e. of three wells and each experiment has been
repeated 2-6 times.
Statistical analysis ofdata
Response to a single mitogen was analysed for significance
by comparing means of treated cells with the mean of control
samples by Student's t-test. Response to two or more mito-
gens were analysed for significance by one way analysis of
variance and comparing the means of treatment groups by
Tukeys test.
Results
Receptor expression
All the cell lines expressed between 7,000 and 102,000 EGF
receptors per cell (Table I). They also all expressed IGF-I
receptor but at a lower level 170-1,300 per cell (Table I).
There was no correlation between the number of EGF recep-
tors and the number of IGF-I receptors on the cell lines
although only five of the cell lines were studied for both
receptors. There was no difference in the number of each
type of receptor between the gastric and colorectal tumours.
Growth response to TGFa and IGF-I
TGFx was mitogenic for C146, St42 and MKN45 cells
(Figure 1). St42 responded the best (mean peak responses of
four experiments 186 ± 23%; P<0.02 compared to untreat-
ed cells: Figure 1), then C146 (mean of four experiments
137 ± 1.3%; P<0.001 compared to untreated cells: Figure 1)
and the established cell line MKN45 was just significant
(mean of three experiments 126 ± 7%; P<0.01 compared to
untreated cells: Figure 1). The optimal dose was between
1-10 ng ml-'. The doubling time of C146 cells was reduced
from 48 h to 30 h in the presence of 1Ongml-' TGFx
(Figure 2) with significantly higher cell numbers being
obtained at both day 2 and 4 (P<0.01).
IGF-I was also mitogenic for all three cell lines. St42 again
responded the most efficently (mean peak response of four
experiments 173 ± 6%; P<0.001 compared to untreated
cells: Figure 3), then C146 (mean four experiments 154 +
10%; P<0.002 compared to untreated cells: Figure 3) and
finally MKN45 (mean of three experiments 138 ± 6%; P<
0.002 compared to untreated cells: Figure 3). Ten ngml-' of
IGF-I again reduced the doubling time of C146 cells from
48 h to 34 h (Figure 4) with significantly higher cell numbers
being obtained at both day 2 and 4 (P<0.01).
Table I Growth factor receptor expression on a series ofgastric and
colorectal human tumour cell lines
Number ofReceptors/cell'
EGF receptor IGF-I receptors
Colorectal cell lines
C146 39,300 740
C168 20,250 1300
C280 28,150 170
C170 7,100 ND'
C277 101,950 ND
C523 ND 720
C560 ND 260
Gastric cell lines
Stl6 ND 250
St42 7,780 190
MKN45 39,700 310
'Receptors were measured by radiolabelled ligand binding assays. tND - denotes not determined.
Figure 1 Proliferation of gastrointestinal cells, C146 (0), St42
(U) and MKN45 (@) in response to TGFa as measured by
75-Se-selenomethionine incorporation. Each line refers to a
representative experiment and each point is a mean of triplicate wells.
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Figure 2 Growth of C146 colorectal tumour cells as measured
by cell counts in serum free medium (M) or in response to TGFa, 0.1 ngml' (0), 1 ngml-' (0), lOngml' (0). The standard
error have been omitted for clarity, but in all cases they were less
than 10% of the mean.
Growth response to combinations ofgastrin, IGF-I and TGFa
Cells were exposed to combinations of TGFa (1Ongml-'), IGF-I (10 ngml-') and gastrin (1-100 ngml-') (Figure 5). The optimum concentration of gastrin for each cell line was
3 ng ml-'. The data were analysed for significance by one
way analysis of variance and the means of treatment groups
were compared by Tukeys test.
When cells were exposed to a combination of IGF-I and TGFax the mitogenic effects were additive for all three cell lines.
C146 and St42, but not MKN45 cells responded trophi- cally to gastrin. However when MKN45 cells were treated with gastrin and either TGFa or IGF-I synergistic stimula- tion of cell growth was observed. In contrast although there
was an additive stimulation of growth by gastrin and TGFa
on C146 cells IGF-I had no effect on gastrin stimulated growth. The reverse was true for St42 cells, only IGF-I added
to the mitogenic effect of gastrin whereas TGFxc had no effect. A combination of all three mitogens gave no further improvement over any combination of two factors.
Discussion
There is increasing evidence that tumour growth is controlled by a series of hormone and growth factors. One of the most
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Figure 3 Proliferation of gastrointestinal cells, C146 (0), St42
(U) and MKN45 (0) in response to IGF-I as measured by
75-Se-selenomethionine incorporation. Each line refers to a
representative experiment and each point is a mean of triplicate
wells.
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Figure 4 Growth of C146 colorectal tumour cells as measured
by cell counts in serum free medium (X) or in response to IGF-I,
0.1ngml-'(0), 1ngml-' (0), 1Ongml-'(0). The standard
error have been omitted for clarity, but in all cases they were less
than 10% of the mean.
important hormones in control of gastrointestinal tumour
growth is the hormone gastrin. However, it remains unclear
if this peptide hormone acts independently of growth factors
or whether they interact. Studies in breast cancer have clearly
shown interactions between the steroid hormone oestrogen
and both the growth factors TGFa and IGF-I (Cormier et
at., 1989; Dickson & Lippman, 1987). This study was design-
ed to examine whether these growth factors could stimulate
gastrointestinal tumour cell proliferation and if they could
increase the sensitivity of cells to gastrin.
All the cell lines expressed both EGE and IGF-I receptors
although the latter were at a much reduced level. This low
number of receptors could have been due to binding of
IGF-I with low affinity to IGE-II or insulin receptors. Scat-
chard analyses are currently being performed to elucidate this
point. However, IGF-I was a potent a mitogen as TGFa in
all three cell lines tested and was therefore binding to some
functional receptor. Gastrin receptors have previously been
detected at similar levels as the IGF-I receptor in both
MKN45 cells and C146 cells (Watson et at., 1989e).
All three cell lines responded mitogenically to both TGFa
and IGF-I with the optimal dose being 10ngml-' when all
the receptors should be occupied. The recently established
gastric cell line responded more strongly than the colorectal
cell line whereas the gastric cell line established 12 years
previously, responded very modestly. Our previous studies
(Watson et al., 1989c) have shown that sensitivity to the
hormone gastrin is lost upon prolonged cell culture in the
absence of the hormone but can be partially recovered by in
vivo growth in nude mice. Coffey et al. (1986) did not see
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Figure 5 Proliferation of gastrointestinal cells, St42 a, C146 b
and MKN45 c in response to combinations of IGF-I
(10 ngml-'); TGFa (10 ng ml ') and gastrin (3 ngml-') as
measured by "-Se-selenomethionine incorporation. The results of
two separate experiment each with triplicate wells are presented
as means of all six wells + standard errors.
stimulation of growth of a colorectal cell line which ex-
pressed EGF receptors. They suggested their cell line was
derived from a metastatic tumour and may have developed
beyond the point of requiring external ligand to bind to
stimulate growth (Coffey et al., 1987).
The mitogenic responses induced by IGF-I and TGFa were
additive suggesting that the two growth factors act inde-
pendently at their different receptors to stimulate cell growth.
Similar results have also been observed for breast cancer cells
(Wakeling et al., 1989).
The colorectal cell line C146 responded modestly to gastrin
but this sensitivity could be enhanced by the addition of a
mitogenic dose of TGFa. MKN45 cells had previously been
shown to respond modestly to gastrin following in vitro
passage in nude mice and cell synchronisation (Watson et al.,
1989c). However the cells used for this study failed to re-
spond to gastrin alone, but there was a significantly higher
response to both IGF-I and TGFa in the presence of gastrin.
Similarly although the recently established gastric cell line
responded modestly to gastrin compared to its response to
IGF-I the proliferative response of these cells to this growth
factor when enhanced in the presence of gastrin. It will be of
interest to see if this is due to stimulation of gastrin receptor
expression or if some intracelluar co-operation is involved.
Synergy between the responses to gastrin and EGF have
previously been reported and this potentiation of cell growth
was suggested to be due to phosphorylation of the gastrin
molecule by EGF stimluated tyrosine kinase (Baldwin et al.,
1983).
Preventing binding and/or secretion of these factors in
conjunction with gastrin may have important therapeutic
potentials. Earlier studies have shown that drugs which alter70 L.G. DURRANT et al.
gastrin secretion (Morris et al., 1989c; Watson et al., 1989d)
or block gastrin binding (Morris et al., 1989a; Watson et al.,
1989aJ) can inhibit growth of human gastrointestinal
tumours growing in nude mice. Whether these drugs or new
drugs can act like the anti-oestrogen drug, tamoxifen, (Lipp-
man et al., 1986; Wakeling et al., 1989) and also prevent
growth factor secretion remains to be examined. In this
context it is interesting that both TGFa and IGF-I have been
suggested as autocrine growth factors for gastrointestinal
cancers. We are currently assaying our cell lines for the
secretion of these growth factors.
Whether these concepts will be useful in the treatment of
gastrointestinal cancer remains to be ascertained; however
the interrelationship of growth factors and hormones on
controlling cell proliferation is vital in the understanding of
gastrointestrinal tumour development and progression.
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